Prioritizing countries for TB vaccine readiness research using a global stakeholder-centric approach
Dados Bibliográficos
| ID | 19592248 |
|---|---|
| Autores | Michelle M Gill (0000-0002-7391-6947, Elizabeth Glaser Pediatric AIDS Foundation, autor correspondente), Rupali J Limaye (0000-0002-3883-9720, Johns Hopkins University, autor correspondente), Rupali Limaye, Puck T Pelzer (0000-0003-1648-0304, TuBerculosis Vaccine Initiative, autor correspondente), Mike Frick (0000-0002-3316-1930, Treatment Action Group, autor correspondente), Andrew D Kerkhoff (0000-0002-5023-6658, San Francisco General Hospital, autor correspondente) |
| Editores | Paulo Jorge Gonçalves de Bettencourt |
| Ano | 2025 |
| Volume | 5 |
| Fascículo | 8 |
| Páginas | e0004668 |
| Data de publicação | 2025-08-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | PLOS Global Public Health (JOURNAL) |
| Identificadores do periódico | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Editora | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0004668 |
| PMID | 40749042 |
| OpenAlex | W4412837377 |
| Idioma | EN |
| Citações recebidas | 1 |
| Referências citadas | 20 |
The promise of new tuberculosis (TB) vaccine candidates prompts the need for research on vaccine demand and health system readiness to help ensure effective and equitable vaccine deployment. We developed an approach to prioritizing countries for TB vaccine readiness research by combining stakeholder preferences, elicited through best-worst scaling (BWS) with an analytical hierarchy process (AHP) framework. We conducted a self-administered electronic survey targeting TB vaccine stakeholders involved in vaccine development, advocacy, and implementation across 23 of the 24 USAID TB priority countries, and key stakeholders working globally. The survey included BWS to determine the relative importance of 17 criteria for country selection. Stakeholders were recruited using an existing email list, a ‘snowball’ approach, and TB experts’ recommendations. In a series of 13 choice tasks, respondents selected the most and least important criteria from four randomly generated criteria. The weights derived through BWS for each criterion were combined with country-specific scores for each criterion using publicly available data to determine the overall prioritization score for each country. Of 427 stakeholders, 115 (26%) completed the survey; 88% were from TB priority countries. Sixteen of 17 criteria were identified as ‘important’ using BWS. Overall country TB burden (weight = 11.1) and TB-related political will (weight = 10.3) were the most important, followed by burden of TB-related deaths (weight = 7.9), health systems strength (weight = 7.5), and adult COVID-19 coverage (weight = 7.4). The five countries with the highest prioritization scores were in sub-Saharan Africa. Three of them were selected alongside the highest-scoring country from South Asia, Europe and Central Asia, and East Asia as priority research settings in pursuit of regional diversity. This study demonstrates the successful use of the AHP combined with BWS, as a practical and transparent approach for prioritizing countries for TB vaccine readiness research which could be applied to support other evidence-based funding decisions in global public health
Business · Developing country · Economic growth · Economics · Environmental health · Global health · Political science · Prioritization · Process management · Public health · Public relations · Snowball sampling · Stakeholder · HIV/AIDS Impact and Responses · Medicine · Nursing · Tuberculosis Research and Epidemiology · Vaccine Coverage and Hesitancy
Statistical Methods for the Analysis of Discrete Choice Experiments
The analytic hierarchy process—what it is and how it is used
Prioritisation processes for programme implementation and evaluation in public health
Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines
Challenges in international health financing and implications for the new pandemic fund
| Obras citantes distintas | 1 |
|---|---|
| Citações por ano | 1 |
| Intervalo de citações | 2026 - 2026 (1) |
| Velocidade de citação | current |
| Altamente citado | Não |